CD19 CAR-T therapy demonstrated non-inferior safety profiles (OR 1.00, 95% CI 0.85–1.17) and comparable partial response achievement (OR 1.10, 95% CI 0.79-1.52) relative to standard-of-care interventions in relapsed/refractory acute lymphoblastic leukemia, with moderate-quality evidence corroborating these findings (Figures 2, 3) (49). Here, CD19 is linked to acute lymphoblastic leukemia.